Ghadeer K Dawwas, Colleen M Brensinger, Ravy K Vajravelu, Qufei Wu, Colleen R Kelly, Loren Laine, Gary D Wu, James D Lewis
BACKGROUND AND AIMS: Fecal microbiota transplantation (FMT) is a commonly used therapy for multiply recurrent Clostridioides difficile (mrCDI). By altering the gut microbiota, there is the potential for FMT to impact the risk for cardiometabolic, intestinal or immune-mediated conditions. Likewise, the microbiota disturbance associated with mrCDI could potentially lead to these conditions. We aimed to assess the associations of mrCDI and FMT with cardiometabolic, immune-mediated diseases, and irritable bowel syndrome...
December 8, 2020: Clinical Gastroenterology and Hepatology